First line hormone therapy vs chemotherapy for HR+HER2-metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count

被引：5

作者：

Bidard, F-C. ^{[1
]}

Brain, E. ^{[1
]}

Jacot, W. ^{[2
]}

Bachelot, T. ^{[3
]}

Ladoire, S. ^{[4
]}

Bourgeois, H. ^{[5
]}

Gonalves, A. ^{[6
]}

Naman, H. ^{[7
]}

Gligorov, J. ^{[8
]}

Dalenc, F. ^{[9
]}

Levy, C. ^{[10
]}

Espie, M. ^{[11
]}

Ferrero, J-M. ^{[12
]}

Luporsi, E. ^{[13
]}

Sablin, M-P. ^{[1
]}

Dubot, C. ^{[1
]}

Chevrier, M. ^{[14
]}

Berger, F. ^{[14
]}

Alix-Panabieres, C. ^{[15
]}

Pierga, J-Y. ^{[1
]}

机构：

[1] Inst Curie, Med Oncol, Paris, France

[2] ICM, Dept Med Oncol, Montpellier, France

[3] Ctr Leon Berard, Med Oncol Serv, Lyon, France

[4] Ctr Georges Francois Leclerc Dijon, Med Oncol, Dijon, France

[5] Clin Victor Hugo Le Mans, Oncol, Le Mans, France

[6] Inst Paoli Calmettes, Oncol Med, Marseille, France

[7] Ctr Azureen Cancerol, Dept Med Oncol, Mougins, France

[8] Tenon Univ Hosp, APHP, Med Oncol, CancerEst, Paris, France

[9] Inst Univ Canc Toulouse Oncopole, Med Oncol, Toulouse, France

[10] Ctr Francois Baclesse, Oncol, Caen, France

[11] Assistance Publ Hop Paris, Med Oncol, Paris, France

[12] Ctr Antoine Lacassagne, Med Oncol, Nice, France

[13] Inst Cancerol Lorraine Alexis Vautrin, Med Oncol, Vandoeuvre Les Nancy, France

[14] Inst Curie, Biostat, Paris, France

[15] Univ Med Ctr Montpellier, Lab Rare Human Circulating Tumor Cells, Montpellier, France

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw365.5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

226PD

引用

页数：1